Tvardi Therapeutics, Inc. (TVRD) AI Stock Analysis

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. Its lead drug candidate is TTI-101, which is in Phase 1b/2 clinical development for fibrosis-driven diseases, focusing initially on idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). The company is also evaluating TTI-109, an oral small molecule STAT3 inhibitor in a Phase-1 clinical trial. Founded in 2017, the company is headquartered in Sugar Land, Texas.

Between FY2020 and FY2024, revenue contracted at a compound annual growth rate of -52.1%, decreasing from $135.1M to $7.1M. Operating results turned from an operating margin of 4.0% and net income of $8.4M in FY2020 to an operating margin of -781.6% and net income of -$70.9M in FY2024. Diluted EPS worsened to -$14.23 in FY2024. For the trailing twelve months ending June 30, 2026, revenue stood at $0, yielding an operating margin of 0.0% and an EPS of -$2.84. Research and development expenses were $32.8M in FY2024, down from $108.4M in FY2023.

As of June 30, 2026, Tvardi Therapeutics held $15.8M in cash and short-term investments and total debt of $145,000, resulting in net cash of $15.6M. The company reported a current ratio of 1.87 and shareholders' equity of $8.4M, with a debt-to-equity ratio of 0.02. Free cash flow was -$62.0M in FY2024, following operating cash flow of -$60.9M. Financing needs have expanded the share count, which grew 838.1% over a 5-year period through FY2025.

At a market capitalization of $13.5M and enterprise value of $1.8M, Tvardi Therapeutics trades at a price-to-sales multiple of 559.6x and an EV-to-revenue multiple of 539.6x, compared to the median of its US-listed Healthcare peers of 4.1x for price-to-sales. Its price-to-book ratio is 2.1x. Over the past year, the stock returned -84.4%, lagging the S&P 500 (SPY) return of 16.8%. Over a 5-year period, the stock declined 99.8%, while the S&P 500 gained 83.0%.

Wall Street coverage includes 5 Strong Buy, 2 Buy, 1 Hold, and 1 Sell ratings. The mean price target is $9.25, indicating an 815.8% upside from the last close of $1.01. Consensus estimates project EPS of -$2.30 on $0 in revenue for the fiscal year ending December 31, 2026, and EPS of -$2.24 on $0 in revenue for next fiscal year among 8 analysts. Over the last four quarters, the company beat EPS estimates once. The next earnings date is November 12, 2026.

This page is an AI-written research summary of Tvardi Therapeutics, Inc. (TVRD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TVRD income statement, TVRD balance sheet, TVRD key metrics, TVRD analyst forecast, TVRD chart. See the TVRD stock overview for the latest quote and news.